Supernus Pharmaceuticals Inc (SUPN) returns
Supernus Pharmaceuticals returns over 10 years
$1,000 invested in Supernus Pharmaceuticals ten years ago was worth $2,035 at the close on October 30, 2026, with dividends reinvested: an average return of 7.4% a year. The same $1,000 in the S&P 500 (SPY) became $4,166.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -2.6% | — | $973.98 | -0.9% |
| 3 months | -8.1% | — | $919.10 | +2.1% |
| Year to date | -15.7% | — | $843.46 | +11.7% |
| 1 year | -25.8% | — | $741.95 | +12.4% |
| 3 years | +77.5% | +21.1% | $1,775 | +88.5% |
| 5 years | +40.4% | +7.0% | $1,404 | +76.0% |
| 10 years | +103.5% | +7.4% | $2,035 | +316.6% |
Supernus Pharmaceuticals return by calendar year
| Year | SUPN | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -15.7% | +11.7% | -27.3% |
| 2025 | +37.4% | +17.7% | +19.7% |
| 2024 | +24.9% | +24.9% | +0.1% |
| 2023 | -18.9% | +26.2% | -45.1% |
| 2022 | +22.3% | -18.2% | +40.5% |
| 2021 | +15.9% | +28.7% | -12.8% |
| 2020 | +6.1% | +18.4% | -12.3% |
| 2019 | -28.6% | +31.2% | -59.8% |
| 2018 | -16.6% | -4.6% | -12.1% |
| 2017 | +57.8% | +21.7% | +36.1% |
| 2016 | +87.9% | +12.0% | +75.9% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: SUPN financials · SUPN valuation
No forecast, no recommendation. This page describes Supernus Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.